Search

Your search keyword '"Sini, Valentina"' showing total 48 results
Start Over Author "Sini, Valentina"
48 results on '"Sini, Valentina"'

1. Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer

Author

Cucciniello, Linda, Blondeaux, Eva, Bighin, Claudia, Gasparro, Simona, Russo, Stefania, Dri, Arianna, Pugliese, Palma, Fontana, Andrea, Cortesi, Enrico, Ferzi, Antonella, Riccardi, Ferdinando, Sini, Valentina, Boni, Luca, Fabi, Alessandra, Montemurro, Filippo, De Laurentiis, Michelino, Arpino, Grazia, Del Mastro, Lucia, Gerratana, Lorenzo, and Puglisi, Fabio

Published
2024
Full Text
View/download PDF

2. The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Author

Molinelli, Chiara, Bruzzone, Marco, Blondeaux, Eva, Ruelle, Tommaso, Lanzavecchia, Chiara, De Laurentiis, Michelino, Russo, Stefania, Riccardi, Ferdinando, Sini, Valentina, Cognetti, Francesco, Arpino, Grazia, Fabi, Alessandra, Pugliese, Palma, Collovà, Elena, Fontana, Andrea, Puglisi, Fabio, Bighin, Claudia, Lambertini, Matteo, and Del Mastro, Lucia

Published
2024
Full Text
View/download PDF

3. Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer: insights from real-world data of a nationwide cohort

Author

Cucciniello, Linda, primary, Blondeaux, Eva, additional, Bighin, Claudia, additional, Gasparro, Simona, additional, Russo, Stefania, additional, Dri, Arianna, additional, Pugliese, Palma, additional, Fontana, Andrea, additional, Cortesi, Enrico, additional, Ferzi, Antonella, additional, Riccardi, Ferdinando, additional, Sini, Valentina, additional, Boni, Luca, additional, Fabi, Alessandra, additional, Montemurro, Filippo, additional, De Laurentiis, Michelino, additional, Arpino, Grazia, additional, Mastro, Lucia Del, additional, Gerratana, Lorenzo, additional, and Puglisi, Fabio, additional

Published
2024
Full Text
View/download PDF

4. Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study

Author

Blondeaux, Eva, Ferreira, Arlindo R., Poggio, Francesca, Puglisi, Fabio, Bighin, Claudia, Sottotetti, Federico, Montemurro, Filippo, Poletto, Elena, Lai, Antonella, Sini, Valentina, Minuti, Gabriele, Mura, Silvia, Fontana, Andrea, Fregatti, Piero, Cardinali, Barbara, Lambertini, Matteo, and Del Mastro, Lucia

Published
2020
Full Text
View/download PDF

5. Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study

Author

Lambertini, Matteo, Ferreira, Arlindo R., Di Meglio, Antonio, Poggio, Francesca, Puglisi, Fabio, Sottotetti, Federico, Montemurro, Filippo, Poletto, Elena, Bernardo, Antonio, Risi, Emanuela, Dellepiane, Chiara, Sini, Valentina, Minuti, Gabriele, Grasso, Donatella, Fancelli, Sara, and Del Mastro, Lucia

Published
2017
Full Text
View/download PDF

7. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

Author

Fabbri, Agnese, primary, Nelli, Fabrizio, additional, Botticelli, Andrea, additional, Giannarelli, Diana, additional, Marrucci, Eleonora, additional, Fiore, Cristina, additional, Virtuoso, Antonella, additional, Scagnoli, Simone, additional, Pisegna, Simona, additional, Alesini, Daniele, additional, Sini, Valentina, additional, Orlandi, Armando, additional, Fabi, Alessandra, additional, Piacentini, Federico, additional, Moscetti, Luca, additional, D’Auria, Giuliana, additional, Gamucci, Teresa, additional, Mazzotta, Marco, additional, Pizzuti, Laura, additional, Vici, Patrizia, additional, Cretella, Elisabetta, additional, Scavina, Paola, additional, La Cesa, Annalisa, additional, Persano, Mara, additional, Atzori, Francesco, additional, and Ruggeri, Enzo Maria, additional

Published
2023
Full Text
View/download PDF

9. Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Author

Di Lisa, Francesca Sofia, primary, Krasniqi, Eriseld, additional, Pizzuti, Laura, additional, Barba, Maddalena, additional, Cannita, Katia, additional, De Giorgi, Ugo, additional, Borella, Fulvio, additional, Foglietta, Jennifer, additional, Cariello, Anna, additional, Ferro, Antonella, additional, Picardo, Elisa, additional, Mitidieri, Marco, additional, Sini, Valentina, additional, Stani, Simonetta, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, La Verde, Nicla, additional, Gambaro, Anna Rita, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Garrone, Ornella, additional, Sarobba, Giuseppina, additional, Livi, Lorenzo, additional, Meattini, Icro, additional, D’Auria, Giuliana, additional, Vergati, Matteo, additional, Gamucci, Teresa, additional, Pistelli, Mirco, additional, Berardi, Rossana, additional, Risi, Emanuela, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Rinaldi, Lucia, additional, Artale, Salvatore, additional, Cazzaniga, Marina Elena, additional, Zustovich, Fable, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Torrisi, Rosalba, additional, Scagnoli, Simone, additional, Botticelli, Andrea, additional, Michelotti, Andrea, additional, Fratini, Beatrice, additional, Saltarelli, Rosa, additional, Paris, Ida, additional, Muratore, Margherita, additional, Cassano, Alessandra, additional, Gianni, Lorenzo, additional, Gaspari, Valeria, additional, Veltri, Enzo Maria, additional, Zoratto, Federica, additional, Fiorio, Elena, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Ruggeri, Enzo Maria, additional, Pedersini, Rebecca, additional, Valerio, Maria Rosaria, additional, Filomeno, Lorena, additional, Minelli, Mauro, additional, Scavina, Paola, additional, Raffaele, Mimma, additional, Astone, Antonio, additional, De Vita, Roy, additional, Pozzi, Marcello, additional, Riccardi, Ferdinando, additional, Greco, Filippo, additional, Moscetti, Luca, additional, Giordano, Monica, additional, Maugeri-Saccà, Marcello, additional, Zennaro, Alessandro, additional, Botti, Claudio, additional, Pelle, Fabio, additional, Cappelli, Sonia, additional, Cavicchi, Flavia, additional, Vizza, Enrico, additional, Sanguineti, Giuseppe, additional, Tomao, Federica, additional, Cortesi, Enrico, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Speranza, Iolanda, additional, Sperduti, Isabella, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2023
Full Text
View/download PDF

11. Abstract P1-11-04: Assessing the clinico-pathological characteristics of HER2 positive metastatic breast cancer patients experiencing radiologic complete response in a nationwide cohort

Author

Cucciniello, Linda, primary, Blondeaux, Eva, additional, Bighin, Claudia, additional, Gasparro, Simona, additional, Russo, Stefania, additional, Dri, Arianna, additional, Pugliese, Palma, additional, Fontana, Andrea, additional, Naso, Giuseppe, additional, Ferzi, Antonella, additional, Riccardi, Ferdinando, additional, Sini, Valentina, additional, Boni, Luca, additional, Fabi, Alessandra, additional, Montemurro, Filippo, additional, De Laurentiis, Michelino, additional, Arpino, Grazia, additional, Mastro, Lucia Del, additional, Gerratana, Lorenzo, additional, and Puglisi, Fabio, additional

Published
2023
Full Text
View/download PDF

14. Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Author

Vici, Patrizia, Pizzuti, Laura, Natoli, Clara, Moscetti, Luca, Mentuccia, Lucia, Vaccaro, Angela, Sergi, Domenico, Di Lauro, Luigi, Trenta, Patrizia, Seminara, Patrizia, Santini, Daniele, Iezzi, Laura, Tinari, Nicola, Bertolini, Ilaria, Sini, Valentina, Mottolese, Marcella, Giannarelli, Diana, Giotta, Francesco, Maugeri-Saccà, Marcello, Barba, Maddalena, Marchetti, Paolo, Michelotti, Andrea, Sperduti, Isabella, and Gamucci, Teresa

Published
2014
Full Text
View/download PDF

16. sj-docx-1-tam-10.1177_17588359211059873 ��� Supplemental material for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Author

Pizzuti, Laura, Krasniqi, Eriseld, Sperduti, Isabella, Barba, Maddalena, Gamucci, Teresa, Mauri, Maria, Veltri, Enzo Maria, Meattini, Icro, Berardi, Rossana, Di Lisa, Francesca Sofia, Natoli, Clara, Pistelli, Mirco, Iezzi, Laura, Risi, Emanuela, D���Ostilio, Nicola, Tomao, Silverio, Ficorella, Corrado, Cannita, Katia, Riccardi, Ferdinando, Cassano, Alessandra, Bria, Emilio, Fabbri, Maria Agnese, Mazzotta, Marco, Barchiesi, Giacomo, Botticelli, Andrea, D���Auria, Giuliana, Ceribelli, Anna, Michelotti, Andrea, Russo, Antonio, Salimbeni, Beatrice Taurelli, Sarobba, Giuseppina, Giotta, Francesco, Paris, Ida, Saltarelli, Rosa, Marinelli, Daniele, Corsi, Domenico, Capomolla, Elisabetta Maria, Sini, Valentina, Moscetti, Luca, Mentuccia, Lucia, Tonini, Giuseppe, Raffaele, Mimma, Marchetti, Luca, Minelli, Mauro, Ruggeri, Enzo Maria, Scavina, Paola, Bacciu, Olivia, Salesi, Nello, Livi, Lorenzo, Tinari, Nicola, Grassadonia, Antonino, Fedele Scinto, Angelo, Rossi, Rosalinda, Valerio, Maria Rosaria, Landucci, Elisabetta, Stani, Simonetta, Fratini, Beatrice, Maugeri-Sacc��, Marcello, De Tursi, Michele, Maione, Angela, Santini, Daniele, Orlandi, Armando, Lorusso, Vito, Cortesi, Enrico, Sanguineti, Giuseppe, Pinnar��, Paola, Cappuzzo, Federico, Landi, Lorenza, Botti, Claudio, Tomao, Federica, Cappelli, Sonia, Bon, Giulia, Pelle, Fabio, Cavicchi, Flavia, Fiorio, Elena, Foglietta, Jennifer, Scagnoli, Simone, Marchetti, Paolo, Ciliberto, Gennaro, and Vici, Patrizia

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-1-tam-10.1177_17588359211059873 for PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting by Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, Maddalena Barba, Teresa Gamucci, Maria Mauri, Enzo Maria Veltri, Icro Meattini, Rossana Berardi, Francesca Sofia Di Lisa, Clara Natoli, Mirco Pistelli, Laura Iezzi, Emanuela Risi, Nicola D���Ostilio, Silverio Tomao, Corrado Ficorella, Katia Cannita, Ferdinando Riccardi, Alessandra Cassano, Emilio Bria, Maria Agnese Fabbri, Marco Mazzotta, Giacomo Barchiesi, Andrea Botticelli, Giuliana D���Auria, Anna Ceribelli, Andrea Michelotti, Antonio Russo, Beatrice Taurelli Salimbeni, Giuseppina Sarobba, Francesco Giotta, Ida Paris, Rosa Saltarelli, Daniele Marinelli, Domenico Corsi, Elisabetta Maria Capomolla, Valentina Sini, Luca Moscetti, Lucia Mentuccia, Giuseppe Tonini, Mimma Raffaele, Luca Marchetti, Mauro Minelli, Enzo Maria Ruggeri, Paola Scavina, Olivia Bacciu, Nello Salesi, Lorenzo Livi, Nicola Tinari, Antonino Grassadonia, Angelo Fedele Scinto, Rosalinda Rossi, Maria Rosaria Valerio, Elisabetta Landucci, Simonetta Stani, Beatrice Fratini, Marcello Maugeri-Sacc��, Michele De Tursi, Angela Maione, Daniele Santini, Armando Orlandi, Vito Lorusso, Enrico Cortesi, Giuseppe Sanguineti, Paola Pinnar��, Federico Cappuzzo, Lorenza Landi, Claudio Botti, Federica Tomao, Sonia Cappelli, Giulia Bon, Fabio Pelle, Flavia Cavicchi, Elena Fiorio, Jennifer Foglietta, Simone Scagnoli, Paolo Marchetti, Gennaro Ciliberto and Patrizia Vici in Therapeutic Advances in Medical Oncology

Published
2021
Full Text
View/download PDF

18. PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Sperduti, Isabella, additional, Barba, Maddalena, additional, Gamucci, Teresa, additional, Mauri, Maria, additional, Veltri, Enzo Maria, additional, Meattini, Icro, additional, Berardi, Rossana, additional, Di Lisa, Francesca Sofia, additional, Natoli, Clara, additional, Pistelli, Mirco, additional, Iezzi, Laura, additional, Risi, Emanuela, additional, D’Ostilio, Nicola, additional, Tomao, Silverio, additional, Ficorella, Corrado, additional, Cannita, Katia, additional, Riccardi, Ferdinando, additional, Cassano, Alessandra, additional, Bria, Emilio, additional, Fabbri, Maria Agnese, additional, Mazzotta, Marco, additional, Barchiesi, Giacomo, additional, Botticelli, Andrea, additional, D’Auria, Giuliana, additional, Ceribelli, Anna, additional, Michelotti, Andrea, additional, Russo, Antonio, additional, Salimbeni, Beatrice Taurelli, additional, Sarobba, Giuseppina, additional, Giotta, Francesco, additional, Paris, Ida, additional, Saltarelli, Rosa, additional, Marinelli, Daniele, additional, Corsi, Domenico, additional, Capomolla, Elisabetta Maria, additional, Sini, Valentina, additional, Moscetti, Luca, additional, Mentuccia, Lucia, additional, Tonini, Giuseppe, additional, Raffaele, Mimma, additional, Marchetti, Luca, additional, Minelli, Mauro, additional, Ruggeri, Enzo Maria, additional, Scavina, Paola, additional, Bacciu, Olivia, additional, Salesi, Nello, additional, Livi, Lorenzo, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Fedele Scinto, Angelo, additional, Rossi, Rosalinda, additional, Valerio, Maria Rosaria, additional, Landucci, Elisabetta, additional, Stani, Simonetta, additional, Fratini, Beatrice, additional, Maugeri-Saccà, Marcello, additional, De Tursi, Michele, additional, Maione, Angela, additional, Santini, Daniele, additional, Orlandi, Armando, additional, Lorusso, Vito, additional, Cortesi, Enrico, additional, Sanguineti, Giuseppe, additional, Pinnarò, Paola, additional, Cappuzzo, Federico, additional, Landi, Lorenza, additional, Botti, Claudio, additional, Tomao, Federica, additional, Cappelli, Sonia, additional, Bon, Giulia, additional, Pelle, Fabio, additional, Cavicchi, Flavia, additional, Fiorio, Elena, additional, Foglietta, Jennifer, additional, Scagnoli, Simone, additional, Marchetti, Paolo, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2021
Full Text
View/download PDF

20. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting

Author

Pizzuti, Laura, primary, Krasniqi, Eriseld, additional, Barchiesi, Giacomo, additional, Della Giulia, Marina, additional, Izzo, Fiorentino, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Mazzotta, Marco, additional, Giusti, Raffaele, additional, Botticelli, Andrea, additional, Gamucci, Teresa, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Tinari, Nicola, additional, Iezzi, Laura, additional, Tomao, Silverio, additional, Tomao, Federica, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Astone, Antonio, additional, Michelotti, Andrea, additional, De Angelis, Claudia, additional, Mentuccia, Lucia, additional, Vaccaro, Angela, additional, Magnolfi, Emanuela, additional, Gelibter, Alain, additional, Magri, Valentina, additional, Cortesi, Enrico, additional, D'Onofrio, Loretta, additional, Cassano, Alessandra, additional, Rossi, Ernesto, additional, Cazzaniga, Marina, additional, Moscetti, Luca, additional, Omarini, Claudia, additional, Piacentini, Federico, additional, Fabbri, Maria A., additional, Scinto, Angelo F., additional, Corsi, Domenico, additional, Carbognin, Luisa, additional, Bria, Emilio, additional, La Verde, Nicla, additional, Samaritani, Riccardo, additional, Garufi, Carlo, additional, Barni, Sandro, additional, Mirabelli, Rosanna, additional, Sarmiento, Roberta, additional, Veltri, Enzo M., additional, D'Auria, Giuliana, additional, Paris, Ida, additional, Giotta, Francesco, additional, Lorusso, Vito, additional, Cardillo, Franca, additional, Landucci, Elisabetta, additional, Mauri, Maria, additional, Ficorella, Corrado, additional, Roselli, Mario, additional, Adamo, Vincenzo, additional, Ricciardi, Giuseppina R.R., additional, Russo, Antonio, additional, Berardi, Rossana, additional, Pistelli, Mirco, additional, Fiorio, Elena, additional, Cannita, Katia, additional, Sini, Valentina, additional, D'Ostilio, Nicola, additional, Foglietta, Jennifer, additional, Greco, Filippo, additional, Zamagni, Claudio, additional, Garrone, Ornella, additional, Di Cocco, Barbara, additional, Baldini, Editta, additional, Livi, Lorenzo, additional, Desideri, Isacco, additional, Meattini, Icro, additional, Sarobba, Giuseppina, additional, Del Medico, Pietro, additional, De Tursi, Michele, additional, Generali, Daniele, additional, De Maria, Ruggero, additional, Risi, Emanuela, additional, Ciliberto, Gennaro, additional, Sperduti, Isabella, additional, Villa, Alice, additional, Barba, Maddalena, additional, Di Leo, Angelo, additional, and Vici, Patrizia, additional

Published
2019
Full Text
View/download PDF

21. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

Author

Pizzuti, Laura, Giordano, Antonio, Michelotti, Andrea, Mazzotta, Marco, Natoli, Clara, Gamucci, Teresa, De Angelis, Claudia, Landucci, Elisabetta, Diodati, Lucrezia, Iezzi, Laura, Mentuccia, Lucia, Fabbri, Agnese, Barba, Maddalena, Sanguineti, Giuseppe, Marchetti, Paolo, Tomao, Silverio, Mariani, Luciano, Paris, Ida, Lorusso, Vito, Vallarelli, Simona, Cassano, Alessandra, Airoldi, Francesca, Orlandi, Armando, Moscetti, Luca, Sergi, Domenico, Sarobba, Maria Giuseppina, Tonini, Giuseppe, Santini, Daniele, Sini, Valentina, Veltri, Enzo, Vaccaro, Angela, Ferrari, Laura, De Tursi, Michele, Tinari, Nicola, Grassadonia, Antonino, Greco, Filippo, Botticelli, Andrea, La Verde, Nicla, Zamagni, Claudio, Rubino, Daniela, Cortesi, Enrico, Magri, Valentina, Pomati, Giulia, Scagnoli, Simone, Capomolla, Elisabetta, Kayal, Ramy, Scinto, Angelo Fedele, Corsi, Domenico Cristiano, Cazzaniga, Marina, Laudadio, Lucio, Forciniti, Samantha, Mancini, Maria, Carbognin, Luisa, Seminara, Patrizia, Barni, Sandro, Samaritani, Riccardo, Roselli, Mario, Portarena, Ilaria, Dello Russo, Antonio, Ficorella, Corrado, Cannita, Katia, Carpano, Silvia, Pistelli, Mirco, Berardi, Rossana, De Maria Marchiano, Ruggero, Sperduti, Isabella, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Orlandi, Armando (ORCID:0000-0001-5253-4678), Corsi, Domenico, De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Pizzuti, Laura, Giordano, Antonio, Michelotti, Andrea, Mazzotta, Marco, Natoli, Clara, Gamucci, Teresa, De Angelis, Claudia, Landucci, Elisabetta, Diodati, Lucrezia, Iezzi, Laura, Mentuccia, Lucia, Fabbri, Agnese, Barba, Maddalena, Sanguineti, Giuseppe, Marchetti, Paolo, Tomao, Silverio, Mariani, Luciano, Paris, Ida, Lorusso, Vito, Vallarelli, Simona, Cassano, Alessandra, Airoldi, Francesca, Orlandi, Armando, Moscetti, Luca, Sergi, Domenico, Sarobba, Maria Giuseppina, Tonini, Giuseppe, Santini, Daniele, Sini, Valentina, Veltri, Enzo, Vaccaro, Angela, Ferrari, Laura, De Tursi, Michele, Tinari, Nicola, Grassadonia, Antonino, Greco, Filippo, Botticelli, Andrea, La Verde, Nicla, Zamagni, Claudio, Rubino, Daniela, Cortesi, Enrico, Magri, Valentina, Pomati, Giulia, Scagnoli, Simone, Capomolla, Elisabetta, Kayal, Ramy, Scinto, Angelo Fedele, Corsi, Domenico Cristiano, Cazzaniga, Marina, Laudadio, Lucio, Forciniti, Samantha, Mancini, Maria, Carbognin, Luisa, Seminara, Patrizia, Barni, Sandro, Samaritani, Riccardo, Roselli, Mario, Portarena, Ilaria, Dello Russo, Antonio, Ficorella, Corrado, Cannita, Katia, Carpano, Silvia, Pistelli, Mirco, Berardi, Rossana, De Maria Marchiano, Ruggero, Sperduti, Isabella, Ciliberto, Gennaro, Vici, Patrizia, Cassano, Alessandra (ORCID:0000-0002-3311-7163), Orlandi, Armando (ORCID:0000-0001-5253-4678), Corsi, Domenico, and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

Published
2019

22. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor‐positive, advanced breast cancer: A real‐world experience

Author

Pizzuti, Laura, primary, Giordano, Antonio, additional, Michelotti, Andrea, additional, Mazzotta, Marco, additional, Natoli, Clara, additional, Gamucci, Teresa, additional, De Angelis, Claudia, additional, Landucci, Elisabetta, additional, Diodati, Lucrezia, additional, Iezzi, Laura, additional, Mentuccia, Lucia, additional, Fabbri, Agnese, additional, Barba, Maddalena, additional, Sanguineti, Giuseppe, additional, Marchetti, Paolo, additional, Tomao, Silverio, additional, Mariani, Luciano, additional, Paris, Ida, additional, Lorusso, Vito, additional, Vallarelli, Simona, additional, Cassano, Alessandra, additional, Aroldi, Francesca, additional, Orlandi, Armando, additional, Moscetti, Luca, additional, Sergi, Domenico, additional, Sarobba, Maria Giuseppina, additional, Tonini, Giuseppe, additional, Santini, Daniele, additional, Sini, Valentina, additional, Veltri, Enzo, additional, Vaccaro, Angela, additional, Ferrari, Laura, additional, De Tursi, Michele, additional, Tinari, Nicola, additional, Grassadonia, Antonino, additional, Greco, Filippo, additional, Botticelli, Andrea, additional, La Verde, Nicla, additional, Zamagni, Claudio, additional, Rubino, Daniela, additional, Cortesi, Enrico, additional, Magri, Valentina, additional, Pomati, Giulia, additional, Scagnoli, Simone, additional, Capomolla, Elisabetta, additional, Kayal, Ramy, additional, Scinto, Angelo Fedele, additional, Corsi, Domenico, additional, Cazzaniga, Marina, additional, Laudadio, Lucio, additional, Forciniti, Samantha, additional, Mancini, Maria, additional, Carbognin, Luisa, additional, Seminara, Patrizia, additional, Barni, Sandro, additional, Samaritani, Riccardo, additional, Roselli, Mario, additional, Portarena, Ilaria, additional, Russo, Antonio, additional, Ficorella, Corrado, additional, Cannita, Katia, additional, Carpano, Silvia, additional, Pistelli, Mirco, additional, Berardi, Rossana, additional, De Maria, Ruggero, additional, Sperduti, Isabella, additional, Ciliberto, Gennaro, additional, and Vici, Patrizia, additional

Published
2018
Full Text
View/download PDF

23. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: A real-world experience

Author

Vici, Patrizia, Pizzuti, Laura, Michelotti, Andrea, Sperduti, Isabella, Natoli, Clara, Mentuccia, Lucia, Di Lauro, Luigi, Sergi, Domenico, Marchetti, Paolo, Santini, Daniele, Magnolfi, Emanuela, Iezzi, Laura, Moscetti, Luca, Fabbri, Agnese, Cassano, Alessandra, Grassadonia, Antonino, Omarini, Claudia, Piacentini, Federico, Botticelli, Andrea, Bertolini, Ilaria, Scinto, Angelo Fedele, Zampa, Germano, Mauri, Maria, D'Onofrio, Loretta, Sini, Valentina, Barba, Maddalena, Maugeri-saccã&nbsp, Marcello, Rossi, Ernesto, Landucci, Elisabetta, Tomao, Silverio, Alberti, Antonio Maria, Giotta, Francesco, Ficorella, Corrado, Adamo, Vincenzo, Russo, Antonio, Lorusso, Vito, Cannita, Katia, Barni, Sandro, Laudadio, Lucio, Greco, Filippo, Garrone, Ornella, Della Giulia, Marina, Marolla, Paolo, Sanguineti, Giuseppe, Di Cocco, Barbara, Ciliberto, Gennaro, De Maria, Ruggero, Gamucci, Teresa, Vici, P., Pizzuti, L., Michelotti, A., Sperduti, I., Natoli, C., Mentuccia, L., Di Lauro, L., Sergi, D., Marchetti, P., Santini, D., Magnolfi, E., Iezzi, L., Moscetti, L., Fabbri, A., Cassano, A., Grassadonia, A., Omarini, C., Piacentini, F., Botticelli, A., Bertolini, I., Scinto, A., Zampa, G., Mauri, M., D'Onofrio, L., Sini, V., Barba, M., Maugeri-Saccà , M., Rossi, E., Landucci, E., Tomao, S., Alberti, A., Giotta, F., Ficorella, C., Adamo, V., Russo, A., Lorusso, V., Cannita, K., Barni, S., Laudadio, L., Greco, F., Garrone, O., Della Giulia, M., Marolla, P., Sanguineti, G., Di Cocco, B., Ciliberto, G., De Maria, R., and Gamucci, T.

Subjects
0301 basic medicine, Oncology, HER2 positive, real-world, medicine.medical_specialty, T-DM1, metastatic breast cancer, previous pertuzumab, Metastatic breast cancer, Previous pertuzumab, Real-world, oncology, ECOG Performance Status, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, Settore MED/04 - PATOLOGIA GENERALE, law, Internal medicine, Medicine, Univariate analysis, Settore MED/06 - ONCOLOGIA MEDICA, business.industry, Cancer, medicine.disease, Log-rank test, trastuzumab, 030104 developmental biology, chemistry, Trastuzumab emtansine, 030220 oncology & carcinogenesis, HER2 positive, Metastatic breast cancer, Previous pertuzumab, Real-world, T-DM1, Oncology, Pertuzumab, business, medicine.drug, Research Paper
Abstract

We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreatment, with median progression-free and median overall survival of 4 and 17 months in pertuzumab-pretreated (p=0.13), and 6 and 22 months in pertuzumab-naïve patients (p=0.27). Patients who received second-line T-DM1 had median progression-free and median overall survival of 3 and 12 months (p=0.0001) if pertuzumab-pretreated, and 8 and 26 months if pertuzumab-naïve (p=0.06). In contrast, in third-line and beyond, median progression-free and median overall survival were 16 and 18 months in pertuzumab-pretreated (p=0.05) and 6 and 17 months in pertuzumab-naïve patients (p=0.30). In multivariate analysis, lower ECOG performance status was associated with progression-free survival benefit (p < 0.0001), while overall survival was positively affected by lower ECOG PS (p < 0.0001), absence of brain metastases (p 0.05), and clinical benefit (p < 0.0001). Our results are comparable with those from randomized trials. Further studies are warranted to confirm and interpret our data on apparently lower T-DM1 efficacy when given as second-line treatment after pertuzumab, and on the optimal sequence order.

Published
2017

24. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer

Author

Gamucci, Teresa, Mentuccia, Lucia, Natoli, Clara, Sperduti, Isabella, Cassano, Alessandra, Michelotti, Andrea, Di Lauro, Luigi, Sergi, Domenico, Fabi, Alessandra, Sarobba, Maria G., Marchetti, Paolo, Barba, Maddalena, Magnolfi, Emanuela, Maugeri‐Saccà, Marcello, Rossi, Ernesto, Sini, Valentina, Grassadonia, Antonino, Pellegrini, Domenica, Astone, Antonino, Nisticò, Cecilia, Angelini, Franco, Vaccaro, Angela, Pellegrino, Arianna, De Angelis, Claudia, Palleschi, Michela, Moscetti, Luca, Bertolini, Ilaria, Buglioni, Simonetta, Giordano, Antonio, Pizzuti, Laura, and Vici, Patrizia

Subjects
Adult, Paclitaxel, Receptor, ErbB-2, Physiology, Clinical Biochemistry, Breast Neoplasms, Disease-Free Survival, Maintenance Chemotherapy, ErbB-2, 80 and over, Humans, Original Research Article, Neoplasm Metastasis, Aged, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Settore MED/06 - ONCOLOGIA MEDICA, Medicine (all), Cell Biology, Middle Aged, Bevacizumab, Treatment Outcome, Multivariate Analysis, Female, Receptor
Abstract

Bevacizumab in combination with taxanes in HER2‐negative metastatic breast cancer (MBC) patients has shown improved progression‐free survival (PFS), despite the lack of clear overall survival (OS) benefit. We performed a retrospective analysis to evaluate the impact of paclitaxel‐bevacizumab and of maintenance therapy with bevacizumab (BM) and endocrine therapy (ET) in the real‐world practice. We identified 314 HER2‐negative MBC patients treated in 12 cancer centers. Overall, the median PFS and OS were 14 and 40 months, respectively. Among the 254 patients potentially eligible for BM, 183 received BM after paclitaxel discontinuation until progression/toxicity. PFS and OS were improved in patients who had received BM in comparison with those potentially eligible but who did not receive BM (P

Published
2017

25. Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumab

Author

Pizzuti, Laura, primary, Sergi, Domenico, additional, Sperduti, Isabella, additional, Lauro, Luigi Di, additional, Mazzotta, Marco, additional, Botti, Claudio, additional, Izzo, Fiorentino, additional, Marchetti, Luca, additional, Tomao, Silverio, additional, Marchetti, Paolo, additional, Natoli, Clara, additional, Grassadonia, Antonino, additional, Gamucci, Teresa, additional, Mentuccia, Lucia, additional, Magnolfi, Emanuela, additional, Vaccaro, Angela, additional, Cassano, Alessandra, additional, Rossi, Ernesto, additional, Botticelli, Andrea, additional, Sini, Valentina, additional, Sarobba, Maria G, additional, Fabbri, Maria Agnese, additional, Moscetti, Luca, additional, Astone, Antonio, additional, Michelotti, Andrea, additional, De Angelis, Claudia, additional, Bertolini, Ilaria, additional, Angelini, Francesco, additional, Ciliberto, Gennaro, additional, Maugeri-Saccà, Marcello, additional, Giordano, Antonio, additional, Barba, Maddalena, additional, and Vici, Patrizia, additional

Published
2018
Full Text
View/download PDF

28. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience

Author

Vici, Patrizia, primary, Pizzuti, Laura, additional, Michelotti, Andrea, additional, Sperduti, Isabella, additional, Natoli, Clara, additional, Mentuccia, Lucia, additional, Lauro, Luigi Di, additional, Sergi, Domenico, additional, Marchetti, Paolo, additional, Santini, Daniele, additional, Magnolfi, Emanuela, additional, Iezzi, Laura, additional, Moscetti, Luca, additional, Fabbri, Agnese, additional, Cassano, Alessandra, additional, Grassadonia, Antonino, additional, Omarini, Claudia, additional, Piacentini, Federico, additional, Botticelli, Andrea, additional, Bertolini, Ilaria, additional, Scinto, Angelo Fedele, additional, Zampa, Germano, additional, Mauri, Maria, additional, D’Onofrio, Loretta, additional, Sini, Valentina, additional, Barba, Maddalena, additional, Maugeri-Saccà, Marcello, additional, Rossi, Ernesto, additional, Landucci, Elisabetta, additional, Tomao, Silverio, additional, Alberti, Antonio Maria, additional, Giotta, Francesco, additional, Ficorella, Corrado, additional, Adamo, Vincenzo, additional, Russo, Antonio, additional, Lorusso, Vito, additional, Cannita, Katia, additional, Barni, Sandro, additional, Laudadio, Lucio, additional, Greco, Filippo, additional, Garrone, Ornella, additional, Giulia, Marina Della, additional, Marolla, Paolo, additional, Sanguineti, Giuseppe, additional, Cocco, Barbara Di, additional, Ciliberto, Gennaro, additional, Maria, Ruggero De, additional, and Gamucci, Teresa, additional

Published
2017
Full Text
View/download PDF

29. 'Triple positive' early breast cancer: An observational multicenter retrospective analysis of outcome

Author

Vici, Patrizia, Pizzuti, Laura, Sperduti, Isabella, Frassoldati, Antonio, Natoli, Clara, Gamucci, Teresa, Tomao, Silverio, Michelotti, Andrea, Moscetti, Luca, Gori, Stefania, Baldini, Editta, Giotta, Francesco, Cassano, Alessandra, Santini, Daniele, Giannarelli, Diana, Di Lauro, Luigi, Corsi, Domenico Cristiano, Marchetti, Paolo, Sini, Valentina, Sergi, Domenico, Barba, Maddalena, Maugeri Saccà, Marcello, Russillo, Michelangelo, Mentuccia, Lucia, D'Onofrio, Loretta, Iezzi, Laura, Scinto, Angelo Fedele, Da Ros, Lucia, Bertolini, Ilaria, Basile, Maria Luisa, Rossi, Valentina, De Maria Marchiano, Ruggero, Montemurro, Filippo, Cassano, Alessandra (ORCID:0000-0002-3311-7163), De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583), Vici, Patrizia, Pizzuti, Laura, Sperduti, Isabella, Frassoldati, Antonio, Natoli, Clara, Gamucci, Teresa, Tomao, Silverio, Michelotti, Andrea, Moscetti, Luca, Gori, Stefania, Baldini, Editta, Giotta, Francesco, Cassano, Alessandra, Santini, Daniele, Giannarelli, Diana, Di Lauro, Luigi, Corsi, Domenico Cristiano, Marchetti, Paolo, Sini, Valentina, Sergi, Domenico, Barba, Maddalena, Maugeri Saccà, Marcello, Russillo, Michelangelo, Mentuccia, Lucia, D'Onofrio, Loretta, Iezzi, Laura, Scinto, Angelo Fedele, Da Ros, Lucia, Bertolini, Ilaria, Basile, Maria Luisa, Rossi, Valentina, De Maria Marchiano, Ruggero, Montemurro, Filippo, Cassano, Alessandra (ORCID:0000-0002-3311-7163), and De Maria Marchiano, Ruggero (ORCID:0000-0003-2255-0583)

Abstract

We recently found that trastuzumab benefit may be lower in a small subset of early breast cancer (BC) patients (pts) with tumors expressing high levels of both hormonal receptors (HRs), i.e. triple positive (TP). To better investigate the role of HRs in HER2 positive BC, we retrospectively identified 872 TP BC pts treated with adjuvant chemotherapy alone (cohort A-366 pts), or plus trastuzumab (cohort B-506 pts). Relapse-free-survival (RFS) and breast-cancer-specific-survival (BCSS) were evaluated. Trastuzumab improved RFS and BCSS in all the subsets analyzed, but the effect on BCSS in tumors expressing both HRs in >30% of cells (TP30), and even on RFS in tumors with both HRs expressed in >50% of cells (TP50) was not significant. Distinct patterns of relapse were observed in TP50 and no-TP50 tumors, the former showing low and constant risk in the first 5 years, a late increase beyond 5 years and modest trastuzumab effect. Trastuzumab effect tended to disappear in pts whose tumors expressed ER in >50% of cells. Multivariate analysis of RFS confirmed a significant interaction between trastuzumab and ER expression, with benefit confined to pts whose tumors expressed ER in ≤50% of cells. Our data suggest that the pattern of relapse of TP tumors with high HRs is similar to that of "luminal", HER2 negative tumors, without clear benefit from adjuvant trastuzumab, which remains the standard treatment even in TP tumors. Confirmatory findings on the extent to which quantitative expression of HRs may impact clinical behavior of HER2 positive BC are warranted.

Published
2016

30. A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer

Author

Gamucci, Teresa, primary, Mentuccia, Lucia, additional, Natoli, Clara, additional, Sperduti, Isabella, additional, Cassano, Alessandra, additional, Michelotti, Andrea, additional, Di Lauro, Luigi, additional, Sergi, Domenico, additional, Fabi, Alessandra, additional, Sarobba, Maria G., additional, Marchetti, Paolo, additional, Barba, Maddalena, additional, Magnolfi, Emanuela, additional, Maugeri-Saccà, Marcello, additional, Rossi, Ernesto, additional, Sini, Valentina, additional, Grassadonia, Antonino, additional, Pellegrini, Domenica, additional, Astone, Antonino, additional, Nisticò, Cecilia, additional, Angelini, Franco, additional, Vaccaro, Angela, additional, Pellegrino, Arianna, additional, De Angelis, Claudia, additional, Palleschi, Michela, additional, Moscetti, Luca, additional, Bertolini, Ilaria, additional, Buglioni, Simonetta, additional, Giordano, Antonio, additional, Pizzuti, Laura, additional, and Vici, Patrizia, additional

Published
2016
Full Text
View/download PDF

31. Bevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons

Author

Sini, Valentina, primary, Cassano, Alessandra, additional, Corsi, Domenico, additional, De Laurentiis, Michele, additional, Gamucci, Teresa, additional, Mauri, Mariella, additional, Naso, Giuseppe, additional, Roselli, Mario, additional, Maria Ruggeri, Enzo, additional, Tonini, Giuseppe, additional, Vici, Patrizia, additional, Zampa, Germano, additional, and Marchetti, Paolo, additional

Published
2016
Full Text
View/download PDF

32. “Triple positive” early breast cancer: an observational multicenter retrospective analysis of outcome

Author

Vici, Patrizia, primary, Pizzuti, Laura, additional, Sperduti, Isabella, additional, Frassoldati, Antonio, additional, Natoli, Clara, additional, Gamucci, Teresa, additional, Tomao, Silverio, additional, Michelotti, Andrea, additional, Moscetti, Luca, additional, Gori, Stefania, additional, Baldini, Editta, additional, Giotta, Francesco, additional, Cassano, Alessandra, additional, Santini, Daniele, additional, Giannarelli, Diana, additional, Di Lauro, Luigi, additional, Corsi, Domenico Cristiano, additional, Marchetti, Paolo, additional, Sini, Valentina, additional, Sergi, Domenico, additional, Barba, Maddalena, additional, Maugeri-Saccà, Marcello, additional, Russillo, Michelangelo, additional, Mentuccia, Lucia, additional, D’Onofrio, Loretta, additional, Iezzi, Laura, additional, Scinto, Angelo Fedele, additional, Da Ros, Lucia, additional, Bertolini, Ilaria, additional, Basile, Maria Luisa, additional, Rossi, Valentina, additional, De Maria, Ruggero, additional, and Montemurro, Filippo, additional

Published
2016
Full Text
View/download PDF

33. PO62 FIRST LINE TRASTUZUMAB-BASED THERAPY IN HER2-POSITIVE METASTATIC BREAST CANCER PATIENTS PRESENTING WITH DE NOVO OR RECURRENT DISEASE: A MULTICENTER RETROSPECTIVE COHORT STUDY

Author

Lambertini, Matteo, primary, Ferreira, Arlindo, additional, Poggio, Francesca, additional, Puglisi, Fabio, additional, Sottotetti, Federico, additional, Poletto, Elena, additional, Pozzi, Emma, additional, Risi, Emanuela, additional, Lai, Antonella, additional, Dellepiane, Chiara, additional, Sini, Valentina, additional, Ziliani, Serena, additional, Minuti, Gabriele, additional, Grasso, Donatella, additional, Fancelli, Sara, additional, Mura, Silvia, additional, Pronzato, Paolo, additional, and Del Mastro, Lucia, additional

Published
2015
Full Text
View/download PDF

35. Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study

Author

Lambertini, Matteo, primary, Ferreira, Arlindo R., additional, Poggio, Francesca, additional, Puglisi, Fabio, additional, Bernardo, Antonio, additional, Montemurro, Filippo, additional, Poletto, Elena, additional, Pozzi, Emma, additional, Rossi, Valentina, additional, Risi, Emanuela, additional, Lai, Antonella, additional, Zanardi, Elisa, additional, Sini, Valentina, additional, Ziliani, Serena, additional, Minuti, Gabriele, additional, Mura, Silvia, additional, Grasso, Donatella, additional, Fontana, Andrea, additional, and Del Mastro, Lucia, additional

Published
2015
Full Text
View/download PDF

36. First line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients (MBC) presenting with de novo or recurrent disease.

Author

Poggio, Francesca, primary, Lambertini, Matteo, additional, Ferreira, Arlindo Rebelo, additional, Puglisi, Fabio, additional, Bernardo, Antonio, additional, Poletto, Elena, additional, Sottotetti, Federico, additional, Risi, Emanuela, additional, Lai, Antonella, additional, Zanardi, Elisa, additional, Sini, Valentina, additional, Ziliani, Serena, additional, Minuti, Gabriele, additional, Dellepiane, Chiara, additional, Grasso, Donatella, additional, Fontana, Andrea, additional, Mura, Silvia, additional, Pronzato, Paolo, additional, and Del Mastro, Lucia, additional

Published
2015
Full Text
View/download PDF

37. Bevacizumab maintenance (BM) in first line treatment for metastatic breast cancer (MBC): A multicenter retrospective observational study.

Author

Mentuccia, Lucia, primary, Fabi, Alessandra, additional, Cassano, Alessandra, additional, Vici, Patrizia, additional, Michelotti, Andrea, additional, Sperduti, Isabella, additional, Sarobba, Maria Giuseppa, additional, Marchetti, Paolo, additional, Rossi, Ernesto, additional, Sini, Valentina, additional, Scognamiglio, Maria Teresa, additional, Pellegrini, Domenica, additional, Giampietro, Jamara, additional, Vaccaro, Angela, additional, Pellegrino, Arianna, additional, Pizzuti, Laura, additional, Palleschi, Michela, additional, Moscetti, Luca I., additional, Nicoletta, Dario, additional, and Gamucci, Teresa, additional

Published
2015
Full Text
View/download PDF

38. Predictive factors of response to neoadjuvant chemotherapy (NAT) in triple negative breast (TNBC) cancer patients: A restrospective multicenter observational study.

Author

Gamucci, Teresa, primary, Mentuccia, Lucia, additional, Vici, Patrizia, additional, Iezzi, Laura, additional, Sperduti, Isabella, additional, Astone, Antonio, additional, Marchetti, Paolo, additional, Pizzuti, Laura, additional, Michelotti, Andrea, additional, Sini, Valentina, additional, Cassano, Alessandra, additional, Ciancola, Fabrizio, additional, Moscetti, Luca I., additional, Quadrini, Silvia, additional, Landucci, Elisabetta, additional, Magnolfi, Emanuela, additional, Sergi, Domenico, additional, and Natoli, Clara, additional

Published
2015
Full Text
View/download PDF

39. Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study

Author

Gamucci, Teresa, primary, Michelotti, Andrea, additional, Pizzuti, Laura, additional, Mentuccia, Lucia, additional, Landucci, Elisabetta, additional, Sperduti, Isabella, additional, Di Lauro, Luigi, additional, Fabi, Alessandra, additional, Tonini, Giuseppe, additional, Sini, Valentina, additional, Salesi, Nello, additional, Ferrarini, Ilaria, additional, Vaccaro, Angela, additional, Pavese, Ida, additional, Veltri, Enzo, additional, Moscetti, Luca, additional, Marchetti, Paolo, additional, and Vici, Patrizia, additional

Published
2014
Full Text
View/download PDF

40. Genetic polymorphisms of EGF 5'-UTR in patients with glioma: A possible predictive marker of outcome.

Author

Vattemi, Emanuela, primary, Cipollini, Giovanna, additional, Dealis, Cristina, additional, Rossi, Lorena, additional, Baier, Susanne, additional, Cretella, Elisabetta, additional, Di Meglio, Giovanni, additional, Sini, Valentina, additional, Lusso, Maria Rita, additional, Ruda, Roberta, additional, Petric, Marija, additional, and Graiff, Claudio, additional

Published
2013
Full Text
View/download PDF

41. Spontaneous immunogenicity of ribosomal P0 protein in patients with benign and malignant breast lesions and delay of mammary tumor growth in P0-vaccinated mice

Author

Marzocchella, Laura, primary, Sini, Valentina, additional, Buonomo, Oreste, additional, Orlandi, Augusto, additional, Masuelli, Laura, additional, Bonanno, Elena, additional, Lista, Florigio, additional, Turriziani, Mario, additional, Manzari, Vittorio, additional, Roselli, Mario, additional, Modesti, Andrea, additional, and Bei, Roberto, additional

Published
2010
Full Text
View/download PDF

42. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

Author

Michele De Tursi, Marco Mazzotta, Armando Orlandi, Marina Elena Cazzaniga, Enrico Cortesi, Maddalena Barba, Laura Iezzi, Giuseppe Tonini, E. Landucci, Lucio Laudadio, Domenico Sergi, Alessandra Cassano, Giuseppe Sanguineti, Nicla La Verde, Riccardo Samaritani, Patrizia Seminara, Antonio Russo, Claudio Zamagni, Simone Scagnoli, Valentina Magri, Ramy Kayal, Enzo Veltri, Francesca Aroldi, Clara Natoli, Ilaria Portarena, Samantha Forciniti, Laura Ferrari, Lucia Mentuccia, Gennaro Ciliberto, Daniele Santini, Teresa Gamucci, Filippo Greco, Silvia Carpano, Mario Roselli, Sandro Barni, A. Fabbri, Isabella Sperduti, A. Vaccaro, Ida Paris, Daniela Rubino, Ruggero De Maria, Patrizia Vici, Claudia De Angelis, Giulia Pomati, Luisa Carbognin, Simona Vallarelli, Antonino Grassadonia, Mirco Pistelli, A.F. Scinto, Katia Cannita, Andrea Michelotti, Domenico Corsi, E. Capomolla, Corrado Ficorella, Nicola Tinari, Vito Lorusso, Rossana Berardi, Andrea Botticelli, Antonio Giordano, Silverio Tomao, Laura Pizzuti, Paolo Marchetti, Maria Giuseppina Sarobba, Valentina Sini, Luca Moscetti, Lucrezia Diodati, Maria Vincenza Mancini, Luciano Mariani, Pizzuti, L, Giordano, A, Michelotti, A, Mazzotta, M, Natoli, C, Gamucci, T, De Angelis, C, Landucci, E, Diodati, L, Iezzi, L, Mentuccia, L, Fabbri, A, Barba, M, Sanguineti, G, Marchetti, P, Tomao, S, Mariani, L, Paris, I, Lorusso, V, Vallarelli, S, Cassano, A, Airoldi, F, Orlandi, A, Moscetti, L, Sergi, D, Sarobba, M, Tonini, G, Santini, D, Sini, V, Veltri, E, Vaccaro, A, Ferrari, L, De Tursi, M, Tinari, N, Grassadonia, A, Greco, F, Botticelli, A, La Verde, N, Zamagni, C, Rubino, D, Cortesi, E, Magri, V, Pomati, G, Scagnoli, S, Capomolla, E, Kayal, R, Scinto, A, Corsi, D, Cazzaniga, M, Laudadio, L, Forciniti, S, Mancini, M, Carbognin, L, Seminara, P, Barni, S, Samaritani, R, Roselli, M, Portarena, I, Russo, A, Ficorella, C, Cannita, K, Carpano, S, Pistelli, M, Berardi, R, De Maria, R, Sperduti, I, Ciliberto, G, Vici, P, Pizzuti, Laura, Giordano, Antonio, Michelotti, Andrea, Mazzotta, Marco, Natoli, Clara, Gamucci, Teresa, De Angelis, Claudia, Landucci, Elisabetta, Diodati, Lucrezia, Iezzi, Laura, Mentuccia, Lucia, Fabbri, Agnese, Barba, Maddalena, Sanguineti, Giuseppe, Marchetti, Paolo, Tomao, Silverio, Mariani, Luciano, Paris, Ida, Lorusso, Vito, Vallarelli, Simona, Cassano, Alessandra, Airoldi, Francesca, Orlandi, Armando, Moscetti, Luca, Sergi, Domenico, Sarobba, Maria Giuseppina, Tonini, Giuseppe, Santini, Daniele, Sini, Valentina, Veltri, Enzo, Vaccaro, Angela, Ferrari, Laura, De Tursi, Michele, Tinari, Nicola, Grassadonia, Antonino, Greco, Filippo, Botticelli, Andrea, La Verde, Nicla, Zamagni, Claudio, Rubino, Daniela, Cortesi, Enrico, Magri, Valentina, Pomati, Giulia, Scagnoli, Simone, Capomolla, Elisabetta, Kayal, Ramy, Scinto, Angelo Fedele, Corsi, Domenico, Cazzaniga, Marina, Laudadio, Lucio, Forciniti, Samantha, Mancini, Maria, Carbognin, Luisa, Seminara, Patrizia, Barni, Sandro, Samaritani, Riccardo, Roselli, Mario, Portarena, Ilaria, Russo, Antonio, Ficorella, Corrado, Cannita, Katia, Carpano, Silvia, Pistelli, Mirco, Berardi, Rossana, De Maria, Ruggero, Sperduti, Isabella, Ciliberto, Gennaro, and Vici, Patrizia

Subjects
Male, 0301 basic medicine, Oncology, Pyridines, Receptor, ErbB-2, Physiology, Clinical Biochemistry, Piperazines, chemistry.chemical_compound, 0302 clinical medicine, Exemestane, Antineoplastic Combined Chemotherapy Protocols, advanced breast cancer, hormonal therapy, endocrine resistance, palbociclib, real-world setting, Breast, Aged, 80 and over, advanced breast cancer, hormonal therapy, Middle Aged, Treatment Outcome, Receptors, Estrogen, 030220 oncology & carcinogenesis, Toxicity, Female, Receptors, Progesterone, medicine.drug, Adult, Cell Biology, medicine.medical_specialty, Breast Neoplasms, Palbociclib, Neutropenia, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Aged, Everolimus, Settore MED/06 - ONCOLOGIA MEDICA, business.industry, Cancer, medicine.disease, Confidence interval, 030104 developmental biology, chemistry, MED/06 - ONCOLOGIA MEDICA, business, Hormone
Abstract

Data from 423 human epidermal growth factor receptor 2-negative (HER2−), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6–35.4) and clinical benefit was 52.7% (95% CI, 48–57.5). ORR was negatively affected by prior exposure to everolimus/exemestane (p = 0.002) and favorably influenced by early line-treatment (p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8–16) and median overall survival was 24 months (95% CI, 17–30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2−, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained.

Published
2019

43. Bevacizumab as first-line treatment in HER2-negative advanced breast cancer: Pros and cons

Author

Germano Zampa, Domenico Corsi, Mario Roselli, Teresa Gamucci, Alessandra Cassano, Valentina Sini, M. Mauri, Giuseppe Naso, Paolo Marchetti, Enzo Maria Ruggeri, Giuseppe Tonini, Patrizia Vici, Michele De Laurentiis, Sini, Valentina, Cassano, Alessandra, Corsi, Domenico, DE LAURENTIIS, Michelino, Gamucci, Teresa, Mauri, Mariella, Naso, Giuseppe, Roselli, Mario, Ruggeri, Enzo Maria, Tonini, Giuseppe, Vici, Patrizia, Zampa, Germano, and Marchetti, Paolo

Subjects
0301 basic medicine, Oncology, Cancer Research, Receptor, ErbB-2, Settore MED/06 - Oncologia Medica, receptor, Angiogenesis Inhibitors, Antineoplastic Agent, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, antibodies, Molecular Targeted Therapy, Triple-negative breast cancer, antineoplastic therapy, bevacizumab, first-line therapy, metastatic breast cancer, overall survival, triple-negative breast cancer, angiogenesis inhibitors, antibodies, monoclonal, antineoplastic agents, antineoplastic combined chemotherapy protocols, breast neoplasms, clinical trials as topic, female, humans, molecular targeted therapy, neoplasm staging, receptor, erbb-2, treatment outcome, medicine (all), oncology, cancer research, Clinical Trials as Topic, biology, Antibodies, Monoclonal, General Medicine, Metastatic breast cancer, Bevacizumab, Treatment Outcome, 030220 oncology & carcinogenesis, Meta-analysis, Female, Antibody, Breast Neoplasm, Angiogenesis Inhibitor, Human, medicine.drug, medicine.medical_specialty, medicine.drug_class, monoclonal, Antineoplastic Agents, Breast Neoplasms, Monoclonal antibody, 03 medical and health sciences, Breast cancer, Internal medicine, medicine, Humans, Neoplasm Staging, Antineoplastic Combined Chemotherapy Protocol, business.industry, Cancer, medicine.disease, 030104 developmental biology, biology.protein, business, erbb-2
Abstract

Purpose Bevacizumab, a humanized, anti-vascular endothelial growth factor-A monoclonal antibody, has shown efficacy in a number of cancers. However, its use in metastatic breast cancer (MBC) remains controversial. Methods A literature review using the PubMed database was performed to update the currently available clinical trials evidence on bevacizumab in the first-line treatment of breast cancer. In addition, the proceedings of selected oncology annual meetings were searched for relevant presentations. Results This article reviews the available evidence for bevacizumab as first-line therapy for MBC and discusses its current and future applicability in the management of MBC. Three phase III trials (ECOG-2100, AVADO, RIBBON-1) demonstrated that the addition of bevacizumab to chemotherapy is well-tolerated and improves progression-free survival and objective response rates in the first-line setting. These findings were supported by a large clinical practice-based study (ATHENA) and a recent clinical trial in which bevacizumab added to paclitaxel showed notable activity in triple-negative MBC. However, bevacizumab has thus far not demonstrated a significant benefit in overall survival. Conclusions The addition of bevacizumab to chemotherapy is well-tolerated and produces substantial improvements in overall response rate and progression-free survival, compared with chemotherapy alone, in advanced HER2-negative breast cancer. Nevertheless, it has thus far not demonstrated a significant benefit in overall survival. Whether prolongation of progression-free survival is enough to consider bevacizumab efficacious is unclear. Based on the available clinical trials results, bevacizumab is a part of the complex therapeutic strategy of advanced HER2-negative breast cancer.

Published
2016

44. Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice

Author

Angelo Di Leo, Carlo Tondini, Michelino De Laurentiis, Pierfranco Conte, Paolo Marchetti, Saverio Cinieri, Valentina Sini, Sini, Valentina, Cinieri, Saverio, Conte, Pierfranco, DE LAURENTIIS, Michelino, Leo, Angelo Di, Tondini, Carlo, and Marchetti, Paolo

Subjects
0301 basic medicine, Oncology, Hormone Responsive, Endocrine therapy, medicine.medical_specialty, Antineoplastic Agents, Hormonal, medicine.drug_class, Maintenance, Drug Resistance, Advanced breastcancer, Endocrine resistance, Hormone receptor positive, Postmenopausal, Treatment, Breast Neoplasms, Drug Resistance, Neoplasm, Female, Humans, Postmenopause, Practice Guidelines as Topic, Hematology, Geriatrics and Gerontology, Estrogen receptor, Antineoplastic Agents, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, Medicine, Endocrine system, Hormonal, business.industry, Cancer, medicine.disease, 030104 developmental biology, Hormone receptor, Estrogen, 030220 oncology & carcinogenesis, Immunology, Neoplasm, business, Breast Neoplasm, Hormone, Human
Abstract

Current international guidelines recommend endocrine therapy as the initial treatment of choice in hormone receptor positive advanced breast cancer. Endocrine therapy has been a mainstay of hormone responsive breast cancer treatment for more than a century. To date it is based on different approaches,such as blocking the estrogen receptor through selective receptor estrogen modulators, depleting extragonadal peripheral estrogen synthesis by aromatase inhibitors or inducing estrogen receptor degradation using selective down-regulators. Despite estrogen and/or progesterone receptor positive status, up to a quarter of patients could be either primarily resistant to hormone therapies or will develop hormone resistance during the course of their disease. Different mechanisms, either intrinsic or acquired, could be implicated in endocrine resistance. In the present work available endocrine therapies and their appropriate sequences have been reviewed, and the most promising strategies to overcome endocrine resistance have been highlighted.

Published
2015

45. Tolerability and Preliminary Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant Therapy: The ATD Study.

Author

Krasniqi E, Filomeno L, Arcuri T, Di Lisa FS, Astone A, Cutigni C, Foglietta J, Nunzi M, Rossi R, Minelli M, Meattini I, Visani L, Scialino J, Livi L, Moscetti L, Marchetti P, Botticelli A, Paris I, Pavese F, D'Angelo T, Sini V, Stani S, Valerio MR, Grassadonia A, Tinari N, Mazzotta M, Vergati M, D'Auria G, Gamucci T, D'Onofrio L, Gasparro S, Roselli A, Fulvi A, Ferretti G, Torchia A, Giordano M, Greco F, Pantano F, Tonini G, Fabbri A, Bria E, Garufi G, Fiorio E, Raffaele M, Pistelli M, Berardi R, Saltarelli R, Kayal R, Ferranti FR, Cannita K, Irelli A, D'Ostilio N, De Rossi C, Palumbo R, Cariello A, Sanguineti G, Calabrò F, Pizzuti L, Barba M, Botti C, Pelle F, Cappelli S, Cavicchi F, Puccica I, Villanucci A, Sperduti I, Ciliberto G, and Vici P

Abstract

Background/objectives: HER2-positive breast cancer (HER2 + BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been established as the standard of care in the adjuvant setting for HER2 + BC patients who do not obtain pCR. The ATD study aimed to evaluate the real-world tolerability of T-DM1 in this setting. The secondary objective was to assess the effectiveness., Methods: This was a multicenter, retrospective study across 24 Italian oncology centers, including 410 patients with HER2 + BC treated with adjuvant T-DM1 following a lack of pCR after NAT. Patient characteristics, NAT regimens, and surgical outcomes were recorded. Tolerability was assessed by documenting adverse events (AEs) according to the CTCAE (v5.0). Preliminary effectiveness was evaluated in terms of relapse-free survival (RFS) and overall survival (OS)., Results: Overall, 228 patients (55.6%) experienced at least one AE related to T-DM1, with 4.9% experiencing grade 3 or higher AEs. The most common AEs were hepatotoxicity (18.5%) and thrombocytopenia (17.6%). T-DM1 was discontinued in 10.0% of patients due to toxicity. After a median follow-up of 25 months, 31 relapse events (7.6%) and 22 deaths (5.4%) were reported. The preliminary incidence of RFS and OS events was similar between patients who completed the T-DM1 course and those who discontinued it early., Conclusions: T-DM1 demonstrated a manageable safety profile, and the adverse events were consistent with those reported in randomized trials. The data are not yet sufficient to allow for a formal analysis of RFS and OS, and long-term follow-up is required.

Published
2024
Full Text
View/download PDF

46. Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Author

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, and Vici P

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor, Breast Neoplasms drug therapy, Breast Neoplasms mortality, Female, Humans, Immunohistochemistry, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Receptor, ErbB-2 metabolism, Receptors, Estrogen metabolism, Receptors, Progesterone metabolism, Breast Neoplasms diagnosis, Breast Neoplasms genetics, Gene Expression Regulation, Neoplastic, Receptor, ErbB-2 genetics, Receptors, Estrogen genetics, Receptors, Progesterone genetics
Abstract

We analyzed data from 738 HER2-positive metastatic breast cancer (mbc) patients treated with pertuzumab-based regimens and/or T-DM1 at 45 Italian centers. Outcomes were explored in relation to tumor subtype assessed by immunohistochemistry (IHC). The median progression-free survival at first-line (mPFS1) was 12 months. Pertuzumab as first-line conferred longer mPFS1 compared to other first-line treatments (16 vs. 9 months, p = 0.0001), regardless of IHC subtype. Median PFS in second-line (mPFS2) was 7 months, with no difference by IHC subtype, but it was more favorable with T-DM1 compared to other agents (7 vs. 6 months, p = 0.03). There was no PFS2 gain in patients with tumors expressing both hormonal receptors (HRs; p = 0.17), while a trend emerged for tumors with one HR (p = 0.05). Conversely, PFS2 gain was significant in HRs-negative tumors (p = 0.04). Median overall survival (mOS) was 74 months, with no significant differences by IHC subtypes. Survival rates at 2 and 3 years in patients treated with T-DM1 in second-line after pertuzumab were significantly lower compared to pertuzumab-naïve patients (p = 0.01). When analyzed by IHC subtype, the outcome was confirmed if both HRs or no HRs were expressed (p = 0.02 and p = 0.006, respectively). Our results confirm that HRs expression impacts the clinical behavior and novel treatment-related outcomes of HER2-positive tumors when treatment sequences are considered. Moreover, multivariate analysis showed that HRs expression had no effect on PFS and OS. Further studies are warranted to confirm our findings and clarify the interplay between HER2 and estrogen receptor pathways in HER2-positive (mbc) patients., (© 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)

Published
2020
Full Text
View/download PDF

47. Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience.

Author

Pizzuti L, Giordano A, Michelotti A, Mazzotta M, Natoli C, Gamucci T, De Angelis C, Landucci E, Diodati L, Iezzi L, Mentuccia L, Fabbri A, Barba M, Sanguineti G, Marchetti P, Tomao S, Mariani L, Paris I, Lorusso V, Vallarelli S, Cassano A, Aroldi F, Orlandi A, Moscetti L, Sergi D, Sarobba MG, Tonini G, Santini D, Sini V, Veltri E, Vaccaro A, Ferrari L, De Tursi M, Tinari N, Grassadonia A, Greco F, Botticelli A, La Verde N, Zamagni C, Rubino D, Cortesi E, Magri V, Pomati G, Scagnoli S, Capomolla E, Kayal R, Scinto AF, Corsi D, Cazzaniga M, Laudadio L, Forciniti S, Mancini M, Carbognin L, Seminara P, Barni S, Samaritani R, Roselli M, Portarena I, Russo A, Ficorella C, Cannita K, Carpano S, Pistelli M, Berardi R, De Maria R, Sperduti I, Ciliberto G, and Vici P

Subjects
Adult, Aged, Aged, 80 and over, Breast metabolism, Breast pathology, Breast Neoplasms metabolism, Disease-Free Survival, Female, Humans, Middle Aged, Receptors, Estrogen drug effects, Receptors, Estrogen metabolism, Receptors, Progesterone drug effects, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms pathology, Piperazines pharmacology, Pyridines pharmacology, Receptor, ErbB-2 metabolism
Abstract

Data from 423 human epidermal growth factor receptor 2-negative (HER2-), hormone receptor-positive (HR+) advanced breast cancer (aBC) patients treated with palbociclib and endocrine therapy (ET) were provided by 35 Italian cancer centers and analyzed for treatment outcomes. Overall, 158 patients were treated in first line and 265 in second/later lines. We observed 19 complete responses and 112 partial responses. The overall response rate (ORR) was 31% (95% confidence interval [CI], 26.6-35.4) and clinical benefit was 52.7% (95% CI, 48-57.5). ORR was negatively affected by prior exposure to everolimus/exemestane ( p = 0.002) and favorably influenced by early line-treatment ( p < 0.0001). At 6 months, median progression-free survival was 12 months (95% CI, 8-16) and median overall survival was 24 months (95% CI, 17-30). More favorable outcomes were associated with palbociclib in early lines, no visceral metastases and no prior everolimus/exemestane. The main toxicity reported was neutropenia. Our results provide further support to the use of palbociclib with ET in HER2-, HR+ aBC. Differences in outcomes across patients subsets remain largely unexplained., (© 2018 Wiley Periodicals, Inc.)

Published
2019
Full Text
View/download PDF

48. Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.

Author

Angelini S, Botticelli A, Onesti CE, Giusti R, Sini V, Durante V, Strigari L, Gentile G, Cerbelli B, Pellegrini P, Sgroi V, Occhipinti M, DI Pietro FR, Rossi A, Simmaco M, Mazzuca F, and Marchetti P

Subjects
ATP Binding Cassette Transporter, Subfamily B genetics, Adult, Aged, Aged, 80 and over, Antineoplastic Agents therapeutic use, Cytochrome P-450 CYP3A genetics, Female, Genotype, Humans, Middle Aged, Pharmacogenetics, Polymorphism, Single Nucleotide, Taxoids therapeutic use, Antineoplastic Agents adverse effects, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Taxoids adverse effects
Abstract

Background: Taxanes are widely used to treat breast cancer patients. Taxanes are metabolized in human liver by the cytochrome CYP3A and are substrate of ATP-binding cassette multidrug transporters ABCB1. Single-nucleotide polymorphisms (SNPs) in genes involved in taxanes' metabolism could affect the inter-individual variability in reported toxicities., Materials and Methods: In this retrospective study, 152 women, affected by breast cancer and receiving a taxane-based chemotherapy, were enrolled. A peripheral blood sample was taken for genotyping the following polymorphisms: CYP3A4* 1B (A>G), CYP3A5 *3 (G>A) and ABCB1 (C1236T; C3435T)., Results: We observed an association between ABCB1 3435 T/T and lower grade of toxicities (p=0.05). No other association were found for CYP 3A4 *1B, 3A5*3 and ABCB1 C1236T., Conclusion: ABCB1 3435 T/T seems to be associated to lower rate of toxicity in patients receiving taxanes. Further prospective and larger studies should be performed to clarify the role of this polymorphism., (Copyright© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results